<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    Why did INM's operating expenses drop sharply in Q4 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/9/2025 03:29am
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">InMed Pharmaceuticals Inc. (INM) did not report any operating expenses in Q4 2024. According to the information available, the company's operating expenses remained high at $2.23 million for Q1 2025, which indicates that the company is still facing challenges with operating losses and cash flow. However, no specific information regarding the operating expenses in Q4 2024 was found in the search results. It is possible that the company's operating expenses were not significant or were reported differently in the financial statements. Without further information, it is difficult to provide a definitive answer to the question.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao,ap,aq,ar,as,at,au){return {layout:"default",data:[{noData:c,currentQuestion:e,textDescription:H,comeFrom:"AInvestShareLink",events:[],answerSource:l}],fetch:{},error:m,state:{sharePreviewModule:{loadJgySuccess:f,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:w,agent_id:a,output_media_info:[],task_id:a,language:a,source:l,cache_builder:a,reply_action:"Answer",execute_mode:x,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"Why did INM's operating expenses drop sharply in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"Why did INM's operating expenses drop sharply in Q4 2024?\",\"user_id\":\"dp50442677\",\"user_name\":\"\",\"trace_id\":\"81d7fc13-f6f6-40de-b7b3-fc300bc587b0\",\"session_id\":\"81d7fc13-f6f6-40de-b7b3-fc300bc587b0\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"query_data",query_type:y,text:"0 results found:\n",query_data:{number:I,title:z,query_type:y,condition:a,model_sql:J,data_ext_params:{merge_repeat:c,expand_index:b,data_add:w,add_index:f}}},{info_type:"search",raw_data:{number:K,title:L,summary:M,full_summary:"Inmed Pharmaceuticals Inc. ( (INM) ) has released its Q1 earnings. Here is a breakdown of the information Inmed Pharmaceuticals Inc. presented to its investors. Invest with Confidence: Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return. Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights. InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company based in Vancouver, Canada, specializing in the development of prescription-based products that include rare cannabinoids and novel cannabinoid analogs targeting diseases with high unmet medical needs, alongside proprietary manufacturing technologies. The latest quarterly earnings report highlights a reduction in net loss compared to the previous year, with the company reporting a net loss of $1.7 million for the quarter ending September 30, 2024, an improvement from the $2.5 million loss in the same period in 2023. The company’s sales increased to $1.26 million from $901,862, indicating a growth trajectory in its commercial operations. Despite the positive sales growth, the company continues to face challenges with operating losses and cash flow, with operating expenses remaining high at $2.23 million. As of September 30, 2024, InMed had $5.6 million in cash and short-term investments, which is expected to fund operations through the first quarter of calendar 2025. Looking forward, InMed’s management remains focused on securing additional financing to support ongoing operations and continuing to explore strategic partnerships to bolster its financial position and operational capabilities.",url:N,image_url:a,video_url:a,publish_time:O,search_extra_info:{search_burial_info:{id:A,uid:P,ab:{scene_id:Q,layer_exp:[{layer_id:R,exp_id:S}]}}},simhash:"ee946954e854e01c",msg_id:A}}],answer_chain_name:T,agent_mode:U,native_answer:a,come_from:a,text_answer:H,trace_id:g,cost:15202,event_names:a,question:e,fallback_type:V,input_type:W,fall_back_reason:{fall_back_type:V,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:g,first_return_cost:2981,cache_type:"no_cache",question_id:g,transfer_question:e,signal_type:"ON_COMPLETE",start_time:B,remote_svc:l,slots:[],answer_type:x,user_id:s,skill_name:C},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:g,session_id:g,user_id:s,question:e,source:l,raw_question:e,version:"3.4.1",action_name:C,nlu:{entity:[{type:X,value:"INM.O",market:Y}]},output_time:B,deep_research:c,deep_thinking:c,agent_mode:U},extra:{}},{answer_path:h,section:{id:i,info_texts:["Thinking"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:h,section:{id:i,info_texts:["Querying Stock: INM Latest Report Period"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:D},logs:[],extra:{action:Z,action_input:"INM Latest Report Period",thought:"The user wants to analyze why INM's operating expenses decreased significantly in Q4 2024. I should focus on the latest report period to obtain the relevant data and information. I will use FinQuery for the latest report period. Then, I will use FinQuery for the operating expenses and search for the reason behind it."}},{answer_path:d,section:{id:E,info_texts:[],show_type:t,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:h,section:{id:i,info_texts:["Querying Stock: INM Operating Expenses in 2024Q4"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:D},logs:[],extra:{action:Z,action_input:z,thought:_}},{answer_path:h,section:{id:i,info_texts:["Searching Web: InMed operating expenses decrease reason in Q4 2024"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:D},logs:[],extra:{action:"Searching Web",action_input:"InMed operating expenses decrease reason in Q4 2024",thought:_}},{answer_path:d,section:{id:E,info_texts:[],show_type:t,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:E,info_texts:[],show_type:t,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:h,section:{id:i,info_texts:["Generating Answer"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:d,section:{id:u,info_texts:[],show_type:n,voice_txt:"In",text_answer:$,rich_text:$,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:aa,info_texts:[],show_type:n,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{title:z,query_type:y,trace_data:a,index:I,model_sql:J,data_ext_params:{merge_repeat:c,expand_index:b,data_add:w,add_index:f},jump_type:"data_query"}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:u,info_texts:[],show_type:n,voice_txt:". According",text_answer:ab,rich_text:ab,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:aa,info_texts:[],show_type:n,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:N,image_url:a,video_url:a,title:L,summary:M,index:K,publish_time:O,search_id:A,search_uid:P,search_ab:{scene_id:Q,layer_exp:[{layer_id:R,exp_id:S}]},jump_type:"normal"}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:u,info_texts:[],show_type:n,voice_txt:". However",text_answer:ac,rich_text:ac,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:d,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"INM",market_id:Y,name:ad,domain:X},pos:f,section_id:u,txt:ad,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:h,section:{id:i,info_texts:["Completed"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:o,query_text:o,trace_info:{item_id:"20eb3bc7d279ec5a4a34906270ce21f3",item_type:k,item_name:o,rec_info:ae}},{display_text:p,query_text:p,trace_info:{item_id:"19603772dd896ef49721244f4b1f4b6b",item_type:k,item_name:p,rec_info:af}},{display_text:q,query_text:q,trace_info:{item_id:"e325575f06d0d2cda7b217b8fd2a8b7f",item_type:k,item_name:q,rec_info:ag}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:f,type:"1",display2:c,url:a}},request_config:[{source_type:ah,related_name:ai}],puuid:F,tag:a,category:"custom",uuid:aj}],global:{urp_static_data:[{name:ai,value:{status_code:f,columns:[{type:r,index_name:ak,key:ak},{type:r,index_name:al,key:al},{type:r,index_name:am,key:am},{type:r,index_name:an,key:an},{type:r,index_name:ao,key:ao}],datas:[{send_text:o,item_type:k,rec_info:ae,display_text:o,rec_reason:a},{send_text:p,item_type:k,rec_info:af,display_text:p,rec_reason:a},{send_text:q,item_type:k,rec_info:ag,display_text:q,rec_reason:a}],dataSize:ah,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ap,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:v,"min-height":"100%",position:aq,height:v},isMaterial:c,id:ap,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:f,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:G,componentUuid:aj,script:[{name:ar,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:G,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:G},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:v,position:aq,height:v},isMaterial:b,_id:19,id:ar,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:as,voice_txt:a,tracking_info:{},uuid:F},order:{is_auto:c,render_for:as,chart_type:"command",puuid:F}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:t,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:C,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:x,answer_chain_name:T},is_deep_research:c,deep_thinking:c,create_time:1746732588109},is_last:b}],questionItem:{data:{qStr:e,encodeFlag:c,imageData:m,docsData:[],quoteData:m},tplType:"question"},events:at,agentId:a,param:{entity_info:{},add_info:{ori_question:e},event_list:at,client_ip:a,question:e,user_id:s,user_name:a,trace_id:g,session_id:g,source:l,input_type:W}}],userId:s,userName:a,startTime:B,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:m,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:f,traceTableData:m,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fwhy-did-inms-operating-expenses-drop-sharply-in-q4-2024-e5d7ca\u002F",config:{_app:{basePath:au,assetsPath:au,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"other\u002FopenAnswer","Why did INM's operating expenses drop sharply in Q4 2024?",0,"81d7fc13-f6f6-40de-b7b3-fc300bc587b0","progress\u002Fsearching_for",1000,"searching_for","llm_generated","ths_ainvest_lite_web",null,"rich_text","How might INM's reduced operating expenses impact its future profitability?","What were INM's operating expenses in Q4 2024?","How do INM's Q4 2024 operating expenses compare to previous quarters?","STR","dp50442677","signal",2001,"auto",1,"agent","intusstock","INM Operating Expenses in 2024Q4","862e08f0890a189a_0",1746732572907,"inspect stocks","thinking",999,"39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","InMed Pharmaceuticals Inc. (INM) did not report any operating expenses in Q4 2024. According to the information available, the company's operating expenses remained high at $2.23 million for Q1 2025, which indicates that the company is still facing challenges with operating losses and cash flow. However, no specific information regarding the operating expenses in Q4 2024 was found in the search results. It is possible that the company's operating expenses were not significant or were reported differently in the financial statements. Without further information, it is difficult to provide a definitive answer to the question.",2,"select   stock_code,   operating_expenses from   ustock_fin_data where   report_end_date = date('2024y4q')   and stock_code = 'INM.O'",5,"InMed Pharmaceuticals Reports Improved Quarterly Earnings","Inmed Pharmaceuticals Inc. ( (INM) ) has released its Q1 earnings. Here is a breakdown of the information Inmed Pharmaceuticals Inc. presented to its investors. Invest with Confidence: Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return. Join thousands of data...","https:\u002F\u002Fwww.tipranks.com\u002Fnews\u002Fcompany-announcements\u002Finmed-pharmaceuticals-reports-improved-quarterly-earnings","2024-11-18","862e08f0890a189a","oeqxkhszf","oeqxkhszf_layer","base","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite","stock","186","Querying Stock","I have obtained the latest report period of INM is 2025Q2. Now I will use FinQuery to obtain the operating expenses data in 2024Q4 and use Search to find the reason behind it.","InMed Pharmaceuticals Inc. (INM) did not report any operating expenses in Q4 2024[^2]",2000,". According to the information available, the company's operating expenses remained high at $2.23 million for Q1 2025, which indicates that the company is still facing challenges with operating losses and cash flow[^5]",". However, no specific information regarding the operating expenses in Q4 2024 was found in the search results. It is possible that the company's operating expenses were not significant or were reported differently in the financial statements. Without further information, it is difficult to provide a definitive answer to the question.","InMed","2+679_496_21_554+0+0+81d7fc13-f6f6-40de-b7b3-fc300bc587b0+20eb3bc7d279ec5a4a34906270ce21f3+llm_generated+aimeTagAnalysis+0+0.007213830016553402+1","2+679_496_21_554+0+0+81d7fc13-f6f6-40de-b7b3-fc300bc587b0+19603772dd896ef49721244f4b1f4b6b+llm_generated+aimeTagAnalysis+0+0.0034066266380250454+2","2+679_496_21_554+0+0+81d7fc13-f6f6-40de-b7b3-fc300bc587b0+e325575f06d0d2cda7b217b8fd2a8b7f+llm_generated+aimeTagAnalysis+0+0.003132093930616975+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>